Chunting Yang

Ms. Chunting Yang

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 July 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
LCLinanni Chen
Linanni Chen
XLXinying Luo
Xinying Luo
JZJiankang Zhang
Jiankang Zhang
JZJinwen Zhang
Jinwen Zhang
CYChunting Yang
Chunting Yang
YZYunqi Zhao
Yunqi Zhao
Cancer nanomedicine holds transformative potential, but its clinical translation remains hindered by the lack of preclinical models that accurately mimic human tumor complexity. Conventional approaches often overlook the dynamic tumor microenvironment (TME) and interpatient variability, leading to unreliable predictions of nanodrug behavior. Here, we present tumor organoids as a transformative solution. These three-dimensional cultures retain the original tumor's architecture, molecular profiles, and TME interactions. Through concrete examples spanning pancreatic, breast, and glioblastoma cancers, we showcase how organoids reliably evaluate nanodrug delivery efficiency, therapeutic effects, and safety profiles. In addition, the establishment of large-scale organoid biobanks further facilitates rapid drug screening and tailored treatment strategies, significantly improving preclinical success rates. Therefore, the organoid-driven paradigm not only overcomes long-standing challenges in tumor modeling but also paves a faster, more reliable path toward clinically effective nanotherapies.

Verified
Journal Article
Open access
PDF file
CYChunting Yang
Chunting Yang
XYXiangyuan Yu
Xiangyuan Yu
EKErica Kleinbrink
Erica Kleinbrink
DKDale King
Dale King
LCLi Chen
Li Chen
LLLeonard Lipovich
Leonard Lipovich
Genome-wide association studies have identified numerous genetic variants statistically significantly associated with body mass index (BMI). However, the functional mechanisms underlying most associations between single nucleotide polymorphisms (SNPs) in non-coding regions and BMI remain poorly understood. Here, we implemented an integrative 7-criterion quantitative scoring system (gene localization, histone modifications, transcription factor binding sites (TFBS), SNP clouds, tissue expression patterns, evolutionary conservation, and COVID-19 associations) to prioritize putative functional loci among 94 BMI-associated SNPs. Six SNPs resided within long non-coding RNA (lncRNA) genes: rs2245368 (exonic, DTX2P1-UPK3BP1-PMS2P11), rs2033529 (exonic, LINC00951), rs2836754 (intronic, ETS2-AS1), rs2815752 (intronic, LINC02796), rs17203016 (intronic, MYOSLID-AS1), and rs7239883 (intronic, LINC00907). We prioritized them because they are located within lncRNA gene bodies and therefore showed stronger functional support compared to other variants which only had non-coding regulatory elements in their vicinity. Notably, rs1928295 exhibited strong GATA2 binding evidence, while rs13201877 had extensive transcription factor occupancy (64 factors). Multiple variants demonstrated putative regulatory potential through epigenomic evidence, including DNase I hypersensitivity and cell-type-specific chromatin accessibility. We show that most BMI risk alleles are not human-specific and are conserved across primates. Our findings suggest putative candidate non-coding regulatory elements in BMI and provide prioritized obesity-associated non-coding variants for functional validations.